Dissecting the interaction between COVID-19 and diabetes mellitus

J Diabetes Investig. 2020 Sep;11(5):1104-1114. doi: 10.1111/jdi.13326. Epub 2020 Aug 5.

Abstract

Coronavirus disease 2019 (COVID-19) is a global pandemic that is caused by a novel coronavirus, severe acute respiratory syndrome coronavirus-2. Data from several countries have shown higher morbidity and mortality among individuals with chronic metabolic diseases, such as diabetes mellitus. In this review, we explore the contributing factors for poorer prognosis in these individuals. As a significant proportion of patients with COVID-19 also have diabetes mellitus, this adds another layer of complexity to their management. We explore potential interactions between antidiabetic medications and renin-angiotensin-aldosterone system inhibitors with COVID-19. Suggested recommendations for the use of antidiabetic medications for COVID-19 patients with diabetes mellitus are provided. We also review pertinent clinical considerations in the management of diabetic ketoacidosis in COVID-19 patients. In addition, we aim to increase clinicians' awareness of the metabolic effects of promising drug therapies for COVID-19. Finally, we highlight the importance of timely vaccinations for patients with diabetes mellitus.

Keywords: COVID-19; Diabetes; SARS-CoV-2.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antiviral Agents / therapeutic use
  • Blood Glucose / metabolism
  • COVID-19 / complications
  • COVID-19 / immunology*
  • COVID-19 / metabolism
  • COVID-19 Drug Treatment
  • COVID-19 Vaccines / therapeutic use
  • Chloroquine / therapeutic use
  • Comorbidity
  • Diabetes Complications / drug therapy
  • Diabetes Complications / immunology*
  • Diabetes Complications / metabolism
  • Diabetes Complications / physiopathology
  • Diabetes Mellitus / drug therapy
  • Diabetes Mellitus / immunology*
  • Diabetes Mellitus / metabolism
  • Diabetes Mellitus / physiopathology
  • Diabetic Ketoacidosis / complications
  • Diabetic Ketoacidosis / therapy
  • Dipeptidyl-Peptidase IV Inhibitors / therapeutic use
  • Drug Combinations
  • Glucagon-Like Peptide-1 Receptor / agonists
  • Glycemic Control
  • Humans
  • Hydroxychloroquine / therapeutic use
  • Hypoglycemic Agents / therapeutic use
  • Insulin / therapeutic use
  • Insulin Resistance
  • Insulin Secretion
  • Interferon Type I / therapeutic use
  • Lopinavir / therapeutic use
  • Lung / physiopathology
  • Metformin / therapeutic use
  • Obesity / complications
  • Obesity / immunology*
  • Obesity / metabolism
  • Obesity / physiopathology
  • Pancreas / metabolism
  • Ritonavir / therapeutic use
  • Severity of Illness Index
  • Sodium-Glucose Transporter 2 Inhibitors / therapeutic use
  • Sulfonylurea Compounds / therapeutic use
  • Thiazolidinediones / therapeutic use

Substances

  • Antibodies, Monoclonal, Humanized
  • Antiviral Agents
  • Blood Glucose
  • COVID-19 Vaccines
  • Dipeptidyl-Peptidase IV Inhibitors
  • Drug Combinations
  • Glucagon-Like Peptide-1 Receptor
  • Hypoglycemic Agents
  • Insulin
  • Interferon Type I
  • Sodium-Glucose Transporter 2 Inhibitors
  • Sulfonylurea Compounds
  • Thiazolidinediones
  • lopinavir-ritonavir drug combination
  • Lopinavir
  • Hydroxychloroquine
  • Chloroquine
  • Metformin
  • tocilizumab
  • Ritonavir